Kinnate Biopharma Top Management
KNTEDelisted Stock | USD 2.96 0.27 8.36% |
Kinnate Biopharma employs about 84 people. The company is managed by 8 executives with a total tenure of roughly 196 years, averaging almost 24.0 years of service per executive, having 10.5 employees per reported executive. Evaluation of Kinnate Biopharma's management performance can provide insight into the firm performance.
Kinnate |
Kinnate Biopharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.3363) % which means that it has lost $0.3363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.558) %, meaning that it created substantial loss on money invested by shareholders. Kinnate Biopharma's management efficiency ratios could be used to measure how well Kinnate Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Kinnate Biopharma Workforce Comparison
Kinnate Biopharma is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 2,194. Kinnate Biopharma holds roughly 84.0 in number of employees claiming about 4% of equities under Health Care industry.
Kinnate Biopharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kinnate Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kinnate Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Kinnate Biopharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Williams Richard Thomas over a year ago Payment of 541 shares by Williams Richard Thomas of Kinnate BiopharmaInc subject to Rule 16b-3 | ||
Tananbaum James B over a year ago Conversion by Tananbaum James B of 166667 shares of Kinnate BiopharmaInc | ||
Williams Richard Thomas over a year ago Payment of 541 shares by Williams Richard Thomas of Kinnate BiopharmaInc subject to Rule 16b-3 | ||
Sabzevari Helen over a year ago Acquisition by Sabzevari Helen of 25000 shares of Kinnate BiopharmaInc subject to Rule 16b-3 | ||
Williams Richard Thomas over a year ago Payment of 541 shares by Williams Richard Thomas of Kinnate BiopharmaInc subject to Rule 16b-3 | ||
Orbimed Advisors Llc over a year ago Purchase by Orbimed Advisors Llc of 83459 shares of Kinnate BiopharmaInc | ||
Orbimed Advisors Llc over a year ago Purchase by Orbimed Advisors Llc of 60998 shares of Kinnate BiopharmaInc | ||
Neha Krishnamohan over a year ago Payment of 1721 shares by Neha Krishnamohan of Kinnate BiopharmaInc subject to Rule 16b-3 |
Kinnate Biopharma Notable Stakeholders
A Kinnate Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kinnate Biopharma often face trade-offs trying to please all of them. Kinnate Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kinnate Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Nima MBA | CEO President | Profile | |
Mark Meltz | General COO | Profile | |
Robert Kania | Senior Research | Profile | |
Richard MBBS | Chief Officer | Profile | |
Jason MD | VP Quality | Profile | |
Neha Krishnamohan | Principal CFO | Profile | |
Barbara Warren | VP Culture | Profile | |
Priyanka Shah | VP Communications | Profile |
About Kinnate Biopharma Management Performance
The success or failure of an entity such as Kinnate Biopharma often depends on how effective the management is. Kinnate Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kinnate management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kinnate management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC. Kinnate Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.
Please note, the presentation of Kinnate Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kinnate Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Kinnate Biopharma's management manipulating its earnings.
Kinnate Biopharma Workforce Analysis
Traditionally, organizations such as Kinnate Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kinnate Biopharma within its industry.Kinnate Biopharma Manpower Efficiency
Return on Kinnate Biopharma Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.3M | |
Net Loss Per Executive | 14.1M | |
Working Capital Per Employee | 1.7M | |
Working Capital Per Executive | 18.3M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |